<DOC>
	<DOCNO>NCT01680861</DOCNO>
	<brief_summary>A recent therapeutic strategy follow renal transplantation include simultaneous use reduce calcineurin inhibitor ( CNI ) dose maximize use non-nephrotoxic , antiproliferative drug ( inosine monophosphate dehydrogenase ( IMPDH ) TOR inhibitor ) , goal reducing/avoiding CNI nephrotoxicity , incidence acute rejection , chronic allograft injury ( CAI ) ( i.e. , interstitial fibrosis/tubular atrophy ) , lead favorable longer-term patient graft survival.1-7 Early corticosteroid withdrawal also use attempt avoid well-known side effect maintain favorable patient graft survival.8-10 While investigator center numerous center also include single agent , antibody induction utilize lymphodepleting polyclonal antibody rabbit anti-human thymocyte globulin ( ATG ) , nondepleting human anti-interleukin-2 receptor ( CD25 ) monoclonal antibody daclizumab ( Dac ) basiliximab , lymphodepleting humanize anti-CD52 monoclonal antibody alemtuzumab,11-17 evidence suggest even effective induction strategy may include combine use one induction agent ( few dos use alone ) , goal bring kidney transplant recipient even closer ( effectively time lymphodepletion ) optimally immunosuppressed state , allow reduction long-term maintenance drug dosing.18-25 The investigator successfully use dual ATG/Dac induction therapy kidney-alone23-24 simultaneous kidney-pancreas ( SPK ) transplantation,18-20 recent report investigator center kidney-alone SPK recipient show addition anti-CD25 ATG induction therapy effectively delay return peripheral blood CD25+ cells.25 In kidney-alone recipient study 3 dos ATG combine 2 dos Dac induction,23-24 vs. investigator previous study utilize single agent induction 7 dos ATG 5 dos Dac.4,16,17 Successful combination ATG/basiliximab dual induction kidney transplantation also report elsewhere,21-22 along equivalency clinical outcome use daclizumab vs. basiliximab.13</brief_summary>
	<brief_title>Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium</brief_title>
	<detailed_description>A . Primary Objectives : 1 . The percentage patient develop chronic allograft injury ( CAI ) progression first 12 month post-transplant protocol biopsy ( i.e. , high grade IF/TA either 6 12 month protocol biopsy comparison baseline biopsy ) . 2 . The incidence rate biopsy-proven acute rejection ( BPAR ) first 12 month post-transplant . B . Secondary Objectives : 1 . Adverse event include graft loss ( death-censored death-uncensored ) , death 12 month post-transplant . 2 . Incidence rate severity ( severity CAI 12 month well ) , base upon careful review clinically indicate protocol biopsy . 3 . Renal function determine serum creatinine estimate glomerular filtration rate ( eGFR ) ( calculate use abbreviated MDRD formula ) 12 , month post-transplant . Use multivariable analysis compare renal function well BPAR CAI progression also perform ( particularly , adjust significant effect donor age , recipient age , race/ethnicity , predictor ) . 5 . Adverse event include withholding ( â‰¥ 28 day ) discontinuance study medication ( reason ) , new onset diabetes mellitus transplantation ( NODAT ) , infection require hospitalization , requirement anti-lipid medication 12 month post-transplant . 6 . Avoidance requirement maintenance corticosteroid therapy renal transplantation . 7 . Allowance reduce maintenance tacrolimus dosing ( rTd ) .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Weight &gt; 40 kg . Deceased donor ( SCD ) LD . Donorrecipient 1 haplotype match pair minimum matching 1 HLA DR antigen . Negative standard cross match T cell . Pretransplant panel reactive antibody &lt; 30 % . Graft require functional , produce least 100ml urine within 24hr transplantation . Previously receive receive organ transplant kidney . Donor organ cold ischemic time &gt; 48 hour . ABO incompatible donor kidney . Recipients T cell , B cell crossmatch positive transplant . Panel reactive antibody ( PRA ) &gt; 30 % HIV Hepatitis C virus , Hepatitis B virus antigenemia . Current malignancy history malignancy Liver disease Uncontrolled concomitant infection and/or severe diarrhea , vomit , active upper gastrointestinal tract malabsorption active peptic ulcer Use warfarin , fluvastatin , herbal supplement study . Use astemizole , pimozide , cisapride , terfenadine , ketoconazole . Hypersensitivity thymoglobulin , IL2 receptor inhibitor monoclonal antibody , tacrolimus , everolimus , MPA , corticosteroid . Pregnant lactating . Abnormal screening/baseline lab WBC , platelet count , triglyceride , cholesterol Double kidney , ECD , pediatric enblock , donation cardiac death ( DCD )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Kidney transplant patient</keyword>
</DOC>